Streetinsider.com After-Hours Movers 2/4: (THO) (CI) (SWI) Higher; (YUM) (BIDU) (HOLX) Lower (more...)
Tweet
Share
E-mail
Get Alerts YUM Hot Sheet
Price: $139.06 +0.40%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 2%
EPS Growth %: +13.2%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 2%
EPS Growth %: +13.2%
Join SI Premium – FREE
Yum! Brands, Inc. (NYSE: YUM) 5% LOWER; Reported Q4 EPS of $0.83, $0.01 better than the analyst estimate of $0.82. Revenue for the quarter came in at $4.15 billion versus the consensus estimate of $4.12 billion. The company estimates a mid-single digit EPS decline in 2013 versus prior year, excluding Special Items.
Thor Industries, Inc. (NYSE: THO) 5% HIGHER; announced preliminary sales, backlog and cash, cash equivalents and investments for the second quarter and six months ended January 31, 2013. Preliminary consolidated sales in the second quarter were $741.4 million, up 24.2% from $597.0 million in the second quarter last year. RV sales were $636.1 million, up 27.0% from $501.0 million in last year's second quarter. Towable RV sales for the second quarter were $522.4 million, up 17.6% from $444.2 million in the second quarter of fiscal 2012. Motorized RV sales in the second quarter more than doubled to $113.7 million from $56.8 million in the same quarter a year ago. Bus sales were $105.3 million, up 9.7% from $96.0 million in the second quarter last year. *** The Street sees Q2 sales of $715.7 million
Baidu.com (NASDAQ: BIDU) 5% LOWER; reported Q4 EPS of $1.31, $0.02 better than the analyst estimate of $1.29. Revenue for the quarter came in at $1.02 billion versus the consensus estimate of $1 billion. Baidu.com sees Q1 2013 revenue of $945.4-975.9 million, versus the consensus of $967.1 million.
Celldex Therapeutics, Inc. (Nasdaq: CLDX) 4% LOWER; announced that it is offering $75,000,000 of its common stock in a proposed underwritten public offering.
Hologic, Inc. (NASDAQ: HOLX) 4% LOWER; reported Q1 EPS of $0.38, in-line with the analyst estimate of $0.38. Revenue for the quarter came in at $631.4 million versus the consensus estimate of $646.52 million. Hologic, Inc. sees FY2013 revenue of $2.61-2.64 billion, versus the consensus of $2.64 billion. sees FY2013 EPS of $1.58 to $1.60, versus the consensus of $1.58. Hologic, Inc. sees Q2 2013 revenue of $635-640 million, versus the consensus of $650.23 million. Sees EPS of $0.33-$0.34 versus the consensus of $0.38.
KCAP Financial, Inc. (Nasdaq: KCAP) 3% LOWER; commenced a public offering of 4,000,000 shares of its common stock. KCAP intends to use the net proceeds of this public offering for general corporate purposes, which includes investing in portfolio companies and collateralized loan obligation funds in accordance with its investment objective and strategies.
Cigna Corporation (NYSE: CI) 3% HIGHER; announced a definitive agreement with Berkshire Hathaway Life Insurance Company of Nebraska, a member of the Berkshire Hathaway, Inc. (NYSE: BRK-A) (NYSE: BRK-B) group (Berkshire), under which Berkshire will reinsure Cigna's Run-off Guaranteed Minimum Death Benefits (VADBe) and Guaranteed Minimum Income Benefits (GMIB) businesses effective February 4, 2013. Cigna will fund this transaction with an incremental $100 million of parent company cash, approximately $1.8 billion of investment assets supporting the run-off businesses, and an estimated $300 million tax benefit associated with the transaction.
Advanced Energy Industries, Inc. (NASDAQ: AEIS) 3% HIGHER; reported Q4 EPS of $0.16, in-line with the analyst estimate of $0.16. Revenue for the quarter came in at $113 million versus the consensus estimate of $111.43 million. Advanced Energy Industries, Inc. sees Q1 2013 EPS of $0.14-0.18, versus the consensus of $0.11. Advanced Energy Industries, Inc. sees Q1 2013 revenue of $105-115 million, versus the consensus of $100.64 million.
Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) 3% LOWER; announced the Company has elected not to continue its clinical development program for IDX184, a nucleotide polymerase inhibitor in phase IIb testing for the treatment of hepatitis C virus (HCV) infection, or to continue its development of IDX19368, an HCV nucleotide polymerase inhibitor for which the Company had previously filed an IND but had not initiated patient dosing.
J.C. Penney Co., Inc. (NYSE: JCP) 2% LOWER; received a letter dated January 29, 2013 from Brown Rudnick LLP claiming to represent holders of more than 50% of the Company`s 7.4% Debentures due 2037. The letter purports to be a Notice of Default under the Indenture for these Debentures dated April 1, 1994 between J. C. Penney Company, Inc. and U. S. Bank National Association as trustee. The Company strongly believes the Notice of Default is invalid and utterly without merit.
Solarwinds (NYSE: SWI) 1% HIGHER; reported Q4 EPS of $0.36, $0.03 better than the analyst estimate of $0.33. Revenue for the quarter came in at $73.5 million versus the consensus estimate of $70.72 million. Solarwinds sees FY2013 revenue of $330-338 million, versus the consensus of $331.54 million. Sees FY2013 EPS of $1.57-$1.62, versus the consensus of $1.54. Solarwinds sees FY2013 revenue of $74.9-75.7 million, versus the consensus of $74.64 million. Sees Q4 EPS of $0.36, versus the consensus of $0.35.
Gilead Sciences, Inc. (NASDAQ: GILD) 1% HIGHER; reported Q4 EPS of $0.50, $0.02 better than the analyst estimate of $0.48. Revenue for the quarter came in at $2.59 billion versus the consensus estimate of $2.43 billion.
Thor Industries, Inc. (NYSE: THO) 5% HIGHER; announced preliminary sales, backlog and cash, cash equivalents and investments for the second quarter and six months ended January 31, 2013. Preliminary consolidated sales in the second quarter were $741.4 million, up 24.2% from $597.0 million in the second quarter last year. RV sales were $636.1 million, up 27.0% from $501.0 million in last year's second quarter. Towable RV sales for the second quarter were $522.4 million, up 17.6% from $444.2 million in the second quarter of fiscal 2012. Motorized RV sales in the second quarter more than doubled to $113.7 million from $56.8 million in the same quarter a year ago. Bus sales were $105.3 million, up 9.7% from $96.0 million in the second quarter last year. *** The Street sees Q2 sales of $715.7 million
Baidu.com (NASDAQ: BIDU) 5% LOWER; reported Q4 EPS of $1.31, $0.02 better than the analyst estimate of $1.29. Revenue for the quarter came in at $1.02 billion versus the consensus estimate of $1 billion. Baidu.com sees Q1 2013 revenue of $945.4-975.9 million, versus the consensus of $967.1 million.
Celldex Therapeutics, Inc. (Nasdaq: CLDX) 4% LOWER; announced that it is offering $75,000,000 of its common stock in a proposed underwritten public offering.
Hologic, Inc. (NASDAQ: HOLX) 4% LOWER; reported Q1 EPS of $0.38, in-line with the analyst estimate of $0.38. Revenue for the quarter came in at $631.4 million versus the consensus estimate of $646.52 million. Hologic, Inc. sees FY2013 revenue of $2.61-2.64 billion, versus the consensus of $2.64 billion. sees FY2013 EPS of $1.58 to $1.60, versus the consensus of $1.58. Hologic, Inc. sees Q2 2013 revenue of $635-640 million, versus the consensus of $650.23 million. Sees EPS of $0.33-$0.34 versus the consensus of $0.38.
KCAP Financial, Inc. (Nasdaq: KCAP) 3% LOWER; commenced a public offering of 4,000,000 shares of its common stock. KCAP intends to use the net proceeds of this public offering for general corporate purposes, which includes investing in portfolio companies and collateralized loan obligation funds in accordance with its investment objective and strategies.
Cigna Corporation (NYSE: CI) 3% HIGHER; announced a definitive agreement with Berkshire Hathaway Life Insurance Company of Nebraska, a member of the Berkshire Hathaway, Inc. (NYSE: BRK-A) (NYSE: BRK-B) group (Berkshire), under which Berkshire will reinsure Cigna's Run-off Guaranteed Minimum Death Benefits (VADBe) and Guaranteed Minimum Income Benefits (GMIB) businesses effective February 4, 2013. Cigna will fund this transaction with an incremental $100 million of parent company cash, approximately $1.8 billion of investment assets supporting the run-off businesses, and an estimated $300 million tax benefit associated with the transaction.
Advanced Energy Industries, Inc. (NASDAQ: AEIS) 3% HIGHER; reported Q4 EPS of $0.16, in-line with the analyst estimate of $0.16. Revenue for the quarter came in at $113 million versus the consensus estimate of $111.43 million. Advanced Energy Industries, Inc. sees Q1 2013 EPS of $0.14-0.18, versus the consensus of $0.11. Advanced Energy Industries, Inc. sees Q1 2013 revenue of $105-115 million, versus the consensus of $100.64 million.
Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) 3% LOWER; announced the Company has elected not to continue its clinical development program for IDX184, a nucleotide polymerase inhibitor in phase IIb testing for the treatment of hepatitis C virus (HCV) infection, or to continue its development of IDX19368, an HCV nucleotide polymerase inhibitor for which the Company had previously filed an IND but had not initiated patient dosing.
J.C. Penney Co., Inc. (NYSE: JCP) 2% LOWER; received a letter dated January 29, 2013 from Brown Rudnick LLP claiming to represent holders of more than 50% of the Company`s 7.4% Debentures due 2037. The letter purports to be a Notice of Default under the Indenture for these Debentures dated April 1, 1994 between J. C. Penney Company, Inc. and U. S. Bank National Association as trustee. The Company strongly believes the Notice of Default is invalid and utterly without merit.
Solarwinds (NYSE: SWI) 1% HIGHER; reported Q4 EPS of $0.36, $0.03 better than the analyst estimate of $0.33. Revenue for the quarter came in at $73.5 million versus the consensus estimate of $70.72 million. Solarwinds sees FY2013 revenue of $330-338 million, versus the consensus of $331.54 million. Sees FY2013 EPS of $1.57-$1.62, versus the consensus of $1.54. Solarwinds sees FY2013 revenue of $74.9-75.7 million, versus the consensus of $74.64 million. Sees Q4 EPS of $0.36, versus the consensus of $0.35.
Gilead Sciences, Inc. (NASDAQ: GILD) 1% HIGHER; reported Q4 EPS of $0.50, $0.02 better than the analyst estimate of $0.48. Revenue for the quarter came in at $2.59 billion versus the consensus estimate of $2.43 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Create E-mail Alert Related Categories
Special ReportsRelated Entities
Warren Buffett, After-Hours MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
